Sponsored by:

Cancer care is evolving rapidly, from the advent of molecular diagnostic tools guiding personalized treatments to novel therapies, and better outcomes are possible. Clinical trials can be a critical entry point for members to access some of these cutting-edge treatments and interventions before they become FDA approved. Benefits leaders who understand the impact of clinical trials in oncology can offer new ways to control costs and improve outcomes for plan members.

In this webcast, we'll demystify clinical trials and explain how benefits advisors and employers can benefit from understanding their potential impact on health outcomes and costs.

Join this webcast to discover how to leverage the latest research to improve health outcomes and reduce healthcare spend.

You'll learn:

• The complexities of navigating clinical trials on behalf of members and what it takes to successfully enroll and clinically benefit
• Obstacles members face in accessing clinical trials, and how to overcome them
• What advisors and benefit leaders should look for in care navigation partners

Register Now!

Speakers

Allyson Ocean, M.D. Dr. Ocean is a medical oncologist and attending physician in gastrointestinal oncology at New York-Presbyterian Hospital/Weill Cornell Medical Center; Associate Professor of Medicine at the Weill Medical College of Cornell University; and medical oncologist at The Jay Monahan Center for Gastrointestinal Health.

Dr. Ocean graduated cum laude from Tufts University. She also graduated with honors from the Tufts University School of Medicine and completed residency in internal medicine at New York-Presbyterian/Weill Cornell Medical Center. Dr. Ocean was chief fellow during her fellowship in hematology and medical oncology at New York-Presbyterian Hospital/Weill Cornell Medical Center.

Dr. Ocean is the author of numerous peer-reviewed articles and abstracts and is an active member of several professional societies, including the American Society of Clinical Oncology, American Society of Hematology, and American Association for Cancer Research.

Natalya Gertsik, PhD | Vice President, ClearCancer Solution | PHM

Dr. Gertsik is an accomplished healthcare professional with expertise in population health risk management, healthcare services, workforce health, & biopharmaceuticals. At PHM, Natalya leads our ClearCancer™ Solution to support organizations in providing the best of what's possible in cancer care to their members. Natalya advises employers on emerging and chronic health risks, providing actionable guidance to optimize cancer care at both the organizational and individual level. This includes improving cancer outcomes and reducing wasteful medical spend, benefits and formulary design, precision medicine adoption, case management approaches, and the use of the latest early detection technologies.

Natalya received her Bachelor of Arts in Biochemistry from New York University and her Doctorate in Biochemistry from Weill Cornell Graduate School of Medical Sciences. Her PhD work focused on Alzheimer's disease drug development and helped illuminate the reasons behind a high-profile Alzheimer's disease drug failure in late-stage clinical trials. Her findings were published in the journal of Cell Chemical Biology.

Erika Sharpe | Senior Clinical Director | PHM

Erika Sharpe is a board-certified nurse practitioner and currently serves as PHM's Senior Clinical Director, overseeing clinical quality. She began her career as a primary care provider in New York City and shifted her focus to cancer care navigation when she joined PHM in 2019. Erika has navigated care across many cancer types and helped patients access novel treatment opportunities. She has expertise supporting patients with rare diseases or who have unusual molecular features where sophisticated care navigation can be particularly impactful.